STAAR Surgical to Report Third Quarter Results on November 3, 2021

Rhea-AI Summary

STAAR Surgical Company (NASDAQ: STAA) will announce its third-quarter financial results on November 3, 2021, after market close. A conference call will follow at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss the results and operational progress. Participants can join the call at 844-200-6205 (domestic) or 929-526-1599 (international). A taped replay will be available for seven days after the call. STAAR focuses on developing implantable lenses and delivery systems to enhance visual freedom, having successfully implanted over 1,000,000 Visian ICLs worldwide.

LAKE FOREST, Calif.--(BUSINESS WIRE)-- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that it will release financial results for the third quarter ended October 1, 2021 on Wednesday, November 3, 2021 after the market close.

STAAR will host a conference call and webcast on Wednesday, November 3 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and operational progress. To access the conference call (Access Code 249252), please dial 844-200-6205 for domestic participants and 929-526-1599 for international participants. The live webcast can be accessed from the investor relations section of the STAAR website at www.staar.com.

A taped replay of the conference call (Replay Code 403818) will be available beginning approximately one hour after the call’s conclusion for seven days. This replay can be accessed by dialing 866-813-9403 for domestic callers and 929-458-6194 for international callers. An archived webcast will also be available at www.staar.com.

About STAAR Surgical

STAAR, which has been dedicated solely to ophthalmic surgery for over 30 years, designs, develops, manufactures and markets implantable lenses for the eye with companion delivery systems. These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR’s lens used in refractive surgery is called an Implantable Collamer® Lens or “ICL”, which includes the EVO Visian ICL™ product line. More than 1,000,000 Visian® ICLs have been implanted to date and STAAR markets these lenses in over 75 countries. To learn more about the ICL go to: www.discovericl.com. Headquartered in Lake Forest, CA, the company operates manufacturing and packaging facilities in Aliso Viejo, CA, Monrovia, CA and Nidau, Switzerland. For more information, please visit the Company’s website at www.staar.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20211020005186/en/

Investors & Media

Brian Moore

Vice President, Investor, Media Relations and Corporate Development

(626) 303-7902, Ext. 3023

bmoore@staar.com

Source: STAAR Surgical Company

FAQ

When will STAAR Surgical announce its Q3 results?

STAAR Surgical will announce its Q3 results on November 3, 2021, after the market close.

What time is the STAAR Surgical Q3 conference call?

The STAAR Surgical Q3 conference call is scheduled for November 3, 2021, at 4:30 p.m. Eastern / 1:30 p.m. Pacific.

How can I access the STAAR Surgical conference call?

To access the STAAR Surgical conference call, dial 844-200-6205 for domestic participants or 929-526-1599 for international callers.

Where can I find the STAAR Surgical financial results webcast?

The webcast for STAAR Surgical's financial results can be accessed on their investor relations section at www.staar.com.

What is the significance of STAAR Surgical's Implantable Collamer Lens?

STAAR Surgical's Implantable Collamer Lens (ICL) provides visual freedom by reducing reliance on glasses or contact lenses; over 1,000,000 have been implanted.